N4 Pharma PLC Asset Resilience Ratio
N4 Pharma PLC asset resilience ratio. N4 Pharma PLC (N4P) has an Asset Resilience Ratio of 0.13% as of December 1990. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See N4 Pharma PLC defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of N4 Pharma PLC (1990–2016)
Asset resilience ratio of N4 Pharma PLC from 1990 to 2016. This chart shows how N4 Pharma PLC's Asset Resilience Ratio has changed over time. Read N4 Pharma PLC (N4P) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down N4 Pharma PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of N4 Pharma PLC.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX20.00K | 0.13% |
| Total Liquid Assets | GBX20.00K | 0.13% |
Asset Resilience Insights
- Limited Liquidity: N4 Pharma PLC maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
N4 Pharma PLC Industry Peers by Asset Resilience Ratio
Compare N4 Pharma PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
N4 Pharma PLC Asset Resilience Ratio by Year (1990–2016)
N4 Pharma PLC asset resilience ratio by year from 1990 to 2016. The table below shows the annual Asset Resilience Ratio data for N4 Pharma PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 20.75% | GBX232.00K ≈ $28.23 |
GBX1.12 Million ≈ $136.03 |
+20.63pp |
| 1990-12-31 | 0.13% | GBX20.00K ≈ $2.43 |
GBX15.85 Million ≈ $1.93K |
-- |
About N4 Pharma PLC
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more